Tallon Kerry Patrick Invests $2.02 Million in Codexis, Inc. (NASDAQ:CDXS)

Tallon Kerry Patrick purchased a new position in Codexis, Inc. (NASDAQ:CDXS) in the 4th quarter, HoldingsChannel.com reports. The firm purchased 403,667 shares of the biotechnology company’s stock, valued at approximately $2,018,000. Codexis accounts for approximately 1.9% of Tallon Kerry Patrick’s investment portfolio, making the stock its 15th biggest position.

Several other institutional investors and hedge funds also recently modified their holdings of CDXS. Bank of New York Mellon Corp grew its stake in shares of Codexis by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 284,166 shares of the biotechnology company’s stock worth $881,000 after purchasing an additional 32,138 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Codexis by 3.8% in the second quarter. Rhumbline Advisers now owns 108,594 shares of the biotechnology company’s stock worth $337,000 after purchasing an additional 4,017 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Codexis by 18.9% in the second quarter. American Century Companies Inc. now owns 100,734 shares of the biotechnology company’s stock worth $312,000 after purchasing an additional 16,019 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Codexis by 34.5% in the second quarter. Dimensional Fund Advisors LP now owns 340,762 shares of the biotechnology company’s stock worth $1,056,000 after purchasing an additional 87,457 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Codexis in the second quarter valued at $89,000. Institutional investors own 78.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CDXS. Cantor Fitzgerald restated an “overweight” rating and issued a $11.00 price objective on shares of Codexis in a report on Friday, November 22nd. Benchmark restated a “hold” rating on shares of Codexis in a report on Monday, November 4th.

Codexis Trading Up 1.0 %

Shares of Codexis stock opened at $4.92 on Friday. The company has a quick ratio of 3.15, a current ratio of 3.21 and a debt-to-equity ratio of 0.39. The firm has a market cap of $400.39 million, a price-to-earnings ratio of -5.66 and a beta of 2.13. The business has a fifty day simple moving average of $4.77 and a 200-day simple moving average of $3.71. Codexis, Inc. has a fifty-two week low of $2.53 and a fifty-two week high of $6.08.

Codexis (NASDAQ:CDXS) last announced its earnings results on Thursday, October 31st. The biotechnology company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.04). Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. The company had revenue of $12.83 million for the quarter, compared to analysts’ expectations of $11.64 million. During the same period in the prior year, the company earned ($0.26) earnings per share. On average, equities analysts forecast that Codexis, Inc. will post -0.77 EPS for the current fiscal year.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.